Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period)Previous forecast published At the earnings announcement on 12 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Although the revision of drug prices had a negative impact on generic drug sales, revenue is expected to remain firm due to the effects of sales promotion activities and other factors. On the profit side, the company had conservatively factored in higher prices for related raw materials resulting from escalating tensions in the Middle East, but each profit measure is expected to exceed the original plan due to some of the impact of cost increases expected in the first half and the signing of a new licensing agreement and the related costs being deferred to the second half, among other factors.
| Item | Details |
|---|---|
| Net Sales | ¥31,500 million → ¥32,300 million（+2.5%） |
| Operating profit | ¥800 million → ¥1,700 million（+112.5%） |
| Ordinary income | ¥600 million → ¥1,400 million（+133.3%） |
| Profit attributable to owners of the parent | ¥500 million → ¥1,000 million（+100.0%） |
| Net income per share | 58.56 Yen/sen → 117.15 Yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) |
| Publication date of previous forecast | At the earnings announcement on 12 May 2026 |
| Previous-period results | Results for the same period of the previous year (second quarter of the fiscal year ending March 2026): revenue of ¥31,229 million, operating profit of ¥1,247 million, ordinary profit of ¥1,131 million, interim net income of ¥831 million and interim earnings per share of ¥97.40 |
| Reason for the revision | Although the revision of drug prices had a negative impact on generic drug sales, revenue is expected to remain firm due to the effects of sales promotion activities and other factors. On the profit side, the company had conservatively factored in higher prices for related raw materials resulting from escalating tensions in the Middle East, but each profit measure is expected to exceed the original plan due to some of the impact of cost increases expected in the first half and the signing of a new licensing agreement and the related costs being deferred to the second half, among other factors. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although the revision of drug prices is expected to have a negative impact on generic drug sales, revenue is expected to remain firm due to the effects of sales promotion activities. On the profit side, the factors include some effects of higher raw material prices coming in below assumptions, and the signing of a new licensing agreement and the related costs being deferred to the second half.